|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SYT17 |
Gene summary for SYT17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SYT17 | Gene ID | 51760 |
| Gene name | synaptotagmin 17 | |
| Gene Alias | Syt-17 | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | H3BN78 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51760 | SYT17 | LZE24T | Human | Esophagus | ESCC | 4.61e-05 | 1.78e-01 | 0.0596 |
| 51760 | SYT17 | P1T-E | Human | Esophagus | ESCC | 3.13e-03 | 3.58e-01 | 0.0875 |
| 51760 | SYT17 | P4T-E | Human | Esophagus | ESCC | 2.51e-03 | 1.50e-01 | 0.1323 |
| 51760 | SYT17 | P5T-E | Human | Esophagus | ESCC | 7.76e-04 | 1.14e-01 | 0.1327 |
| 51760 | SYT17 | P8T-E | Human | Esophagus | ESCC | 3.40e-16 | 3.24e-01 | 0.0889 |
| 51760 | SYT17 | P9T-E | Human | Esophagus | ESCC | 1.79e-02 | 6.63e-02 | 0.1131 |
| 51760 | SYT17 | P12T-E | Human | Esophagus | ESCC | 2.85e-07 | 2.47e-01 | 0.1122 |
| 51760 | SYT17 | P15T-E | Human | Esophagus | ESCC | 6.77e-14 | 3.84e-01 | 0.1149 |
| 51760 | SYT17 | P17T-E | Human | Esophagus | ESCC | 2.91e-02 | 1.34e-01 | 0.1278 |
| 51760 | SYT17 | P20T-E | Human | Esophagus | ESCC | 4.56e-14 | 3.13e-01 | 0.1124 |
| 51760 | SYT17 | P22T-E | Human | Esophagus | ESCC | 2.09e-08 | 1.99e-01 | 0.1236 |
| 51760 | SYT17 | P23T-E | Human | Esophagus | ESCC | 4.88e-15 | 4.06e-01 | 0.108 |
| 51760 | SYT17 | P24T-E | Human | Esophagus | ESCC | 8.11e-06 | 2.04e-01 | 0.1287 |
| 51760 | SYT17 | P26T-E | Human | Esophagus | ESCC | 4.32e-07 | 1.96e-01 | 0.1276 |
| 51760 | SYT17 | P27T-E | Human | Esophagus | ESCC | 4.29e-03 | 1.27e-01 | 0.1055 |
| 51760 | SYT17 | P30T-E | Human | Esophagus | ESCC | 3.17e-03 | 1.27e-01 | 0.137 |
| 51760 | SYT17 | P37T-E | Human | Esophagus | ESCC | 4.35e-02 | 6.99e-02 | 0.1371 |
| 51760 | SYT17 | P39T-E | Human | Esophagus | ESCC | 1.81e-13 | 2.88e-01 | 0.0894 |
| 51760 | SYT17 | P42T-E | Human | Esophagus | ESCC | 1.56e-03 | 9.36e-02 | 0.1175 |
| 51760 | SYT17 | P48T-E | Human | Esophagus | ESCC | 6.76e-09 | 2.34e-01 | 0.0959 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
| GO:003030710 | Esophagus | ESCC | positive regulation of cell growth | 100/8552 | 166/18723 | 1.07e-04 | 7.55e-04 | 100 |
| GO:006056010 | Esophagus | ESCC | developmental growth involved in morphogenesis | 131/8552 | 234/18723 | 9.28e-04 | 4.73e-03 | 131 |
| GO:007124117 | Esophagus | ESCC | cellular response to inorganic substance | 125/8552 | 226/18723 | 2.17e-03 | 9.67e-03 | 125 |
| GO:004858810 | Esophagus | ESCC | developmental cell growth | 125/8552 | 234/18723 | 1.01e-02 | 3.46e-02 | 125 |
| GO:004592717 | Esophagus | ESCC | positive regulation of growth | 137/8552 | 259/18723 | 1.13e-02 | 3.80e-02 | 137 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SYT17 | SNV | Missense_Mutation | novel | c.302C>G | p.Ser101Cys | p.S101C | Q9BSW7 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| SYT17 | SNV | Missense_Mutation | rs149672382 | c.367G>A | p.Asp123Asn | p.D123N | Q9BSW7 | protein_coding | deleterious(0.05) | probably_damaging(0.959) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SYT17 | SNV | Missense_Mutation | rs757778066 | c.529G>A | p.Glu177Lys | p.E177K | Q9BSW7 | protein_coding | tolerated(0.05) | benign(0.018) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| SYT17 | SNV | Missense_Mutation | rs747054767 | c.425N>T | p.Ser142Leu | p.S142L | Q9BSW7 | protein_coding | deleterious(0.02) | benign(0.024) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SYT17 | SNV | Missense_Mutation | c.287N>T | p.Ser96Leu | p.S96L | Q9BSW7 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| SYT17 | SNV | Missense_Mutation | c.512N>C | p.Val171Ala | p.V171A | Q9BSW7 | protein_coding | tolerated(0.37) | benign(0.015) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| SYT17 | deletion | In_Frame_Del | c.605_616delCCGTGCGCGTGA | p.Thr202_Val205del | p.T202_V205del | Q9BSW7 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | |||
| SYT17 | SNV | Missense_Mutation | novel | c.445A>T | p.Asn149Tyr | p.N149Y | Q9BSW7 | protein_coding | deleterious(0.01) | benign(0) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| SYT17 | SNV | Missense_Mutation | rs764083934 | c.194G>A | p.Arg65Gln | p.R65Q | Q9BSW7 | protein_coding | tolerated(0.37) | benign(0) | TCGA-A6-5667-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| SYT17 | SNV | Missense_Mutation | rs775318995 | c.611N>A | p.Arg204His | p.R204H | Q9BSW7 | protein_coding | tolerated(0.11) | benign(0.036) | TCGA-AA-3673-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |